Sugi Predict

Sugi Predict / Compounds / SCHEMBL1008904

SCHEMBL1008904

SCHEMBL1008904

O=C(O)C(CC1CCCC1)n1ncc(Oc2ccccc2N2CCOCC2)cc1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRA1D P25100 2/20 0.41
▸ ADRA1A P35348 2/20 0.41
▸ ADRA1B P35368 2/20 0.41
▸ POLB P06746 3/20 0.40
▸ MAPT P10636 2/20 0.40
▸ ALDH1A1 P00352 4/20 0.38
▸ GAA P10253 3/20 0.38
▸ NPC1 O15118 3/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ NAPEPLD Q6IQ20 1/20 0.35
▸ CPT2 P23786 2/20 0.35
▸ CPT1A P50416 2/20 0.35
▸ AKR1C3 P42330 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ ATM Q13315 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1009333 0.93 ADRA1A (0.43) ADRA1DADRA1AADRA1BPOLBRAB9A
SCHEMBL1009305 0.92 ADRA1A (0.43) ADRA1DADRA1AADRA1BALDH1A1GAA
SCHEMBL1009403 0.82 LPAR1 (0.41) KMT2A
SCHEMBL1007288 0.82 LPAR1 (0.41) —
SCHEMBL1008741 0.82 LPAR1 (0.39) ALDH1A1L3MBTL1KMT2A
SCHEMBL1008265 0.82 FFAR1 (0.40) ALDH1A1KDM4EHTTL3MBTL1SMN1; SMN2
SCHEMBL1008715 0.82 LPAR1 (0.37) ALDH1A1SMN1; SMN2KMT2A
SCHEMBL1009307 0.82 NPY5R (0.43) —
SCHEMBL1008070 0.82 PTGDR2 (0.41) ADRA1AMAPTALDH1A1KMT2A
SCHEMBL4295932 0.81 GCK (0.43) ALDH1A1LMNAHTTL3MBTL1NAPEPLD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 — — EP disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK ADRA1D 1734/4885ADRA1A 1510/4885ADRA1B 1237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.